HC Wainwright Rates Achieve Life Sciences (ACHV) buy

HC Wainwright maintains its buy rating for Achieve Life Sciences with a $12 price target, a 119.38% upside from the current price.

By EarningsIQ Research Desk · Published Jun 22, 2026, 10:02 PM EDT · Updated Jun 25, 2026, 12:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Achieve Life Sciences, Inc. ($ACHV) "buy" with a $12 price target on June 22, 2026.

Since the rating, $ACHV is up 22.2% after 1 week, up 23.7% after 1 month and up 25.1% to date (from the $5.10 close on Jun 22, 2026).

ACHV Achieve Life Sciences, Inc.

$6.38 +28.37% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its buy rating for Achieve Life Sciences (ACHV) with a $12 target on June 22, 2026.
HC Wainwright's $12 price target implies 119.38% upside from Achieve Life Sciences, Inc.'s ($ACHV) current $5.47 share price.
Achieve Life Sciences, Inc. traded at $5.29 on Tuesday, with a market cap of about $523.6 million and a 52-week high of $6.16.
Vanguard Capital Management LLC opened a new position in Achieve Life Sciences with 2,204,714 shares valued at approximately $6.48 million.

Get $ACHV trade alerts by text

We text you when insiders, Congress or big funds trade $ACHV. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Achieve Life Sciences, Inc. alert may contain errors. Disclosures

HC Wainwright has reiterated its buy rating for Achieve Life Sciences, Inc. (NASDAQCM:ACHV), setting a price target of $12. This update came on June 22, 2026, as the firm continues to show confidence in Achieve's potential. On Tuesday, shares of Achieve Life Sciences traded at $5.29.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +53.56% hypothetical

All-time return +155.65% S&P 500 +28.65%

vs. S&P 500 +127% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Achieve Life Sciences

Vanguard Capital Management LLC opened a new position in Achieve Life Sciences, acquiring 2,204,714 shares valued at about $6.48 million. Meanwhile, Millennium Management LLC reduced its holdings by 281,778 shares, leaving it with 1,077,338 shares worth around $3.17 million. Other major holders, including Franklin Resources Inc. and Propel Bio Management, LLC, maintained their positions.

Achieve Life Sciences, Inc. Stock Down 31.5%

Shares of Achieve Life Sciences traded near $5.29 on Tuesday. The company has a market cap of approximately $523.6 million and a forward P/E that is not meaningful due to its lack of profitability. Achieve's beta is 2.264, indicating higher volatility compared to the market. The stock has seen a 52-week low of $2.00 and a high of $6.16, with a 50-day moving average of $4.79 and a 200-day moving average of $4.33.

12-month forecast

$ACHV price target

Achieve Life Sciences, Inc. daily closes and this analyst's $12 target. Not advice.

Insider Buying and Selling at Achieve Life Sciences, Inc.

Several insiders have been active in purchasing shares of Achieve Life Sciences recently. On May 29, 2026, Reid Alexander Waldman and Jeffrey Farrow each bought 47,250 shares. Earlier, on May 11, Christopher Nathan Martin acquired the same number of shares. Additionally, on April 18, CEO Andrew Goldberg made multiple purchases, including 11,706,270 shares.

Analysts Set New Price Targets

On June 22, 2026, HC Wainwright & Co. reiterated its buy rating for Achieve Life Sciences with a $12 price target. Previously, Canaccord Genuity initiated coverage with a buy rating and a $13 target on April 21, 2026. The consensus among analysts, with nine opinions, suggests a mean target price of $13.11.

About Achieve Life Sciences

Achieve Life Sciences, Inc. is a biotechnology company based in Bothell, Washington. It focuses on developing and commercializing cytisinicline, a treatment for nicotine addiction. The company operates in Canada, the United States, and the United Kingdom and has partnerships with Sopharma AD and the University of Bristol. Led by CEO Dr. Andrew D. Goldberg, Achieve has 28 employees.

Bottom Line

HC Wainwright's continued buy rating for Achieve Life Sciences with a $12 target reflects optimism about the company's future. Investors keep an eye on these ratings as they can influence market perceptions. It's important to remember that such analyst ratings are based on past performance and expectations, not real-time data.